New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
06:16 EDTRHHBYGenentech says IDMC recommends Phase III METLung study be stopped
Genentech, a member of the Roche Group, announced that an independent data monitoring committee has recommended that the Phase III METLung study be stopped due to a lack of clinically meaningful efficacy. The study evaluated if onartuzumab in combination with Tarceva helped people with previously treated, advanced non-small cell lung cancer whose tumors were identified as MET-positive live longer compared to Tarceva alone. Overall adverse event rates were generally similar between the two groups. Data will be submitted for presentation at an upcoming medical meeting. "These results are disappointing because new options are needed for people with lung cancer, the most common and deadly cancer worldwide, said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "We remain committed to helping people with lung cancer and are studying several investigational medicines in this disease. Genentech is evaluating the implications of the METLung study results across the ongoing onartuzumab clinical program.
News For RHHBY From The Last 14 Days
Check below for free stories on RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
09:09 EDTRHHBYRoche to hold an investor update
Subscribe for More Information
08:15 EDTRHHBYEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Subscribe for More Information
05:58 EDTRHHBYExelixis shares rallied on Roche rumors, says Piper Jaffray
Subscribe for More Information
July 28, 2014
07:30 EDTRHHBYQ1 Productions to hold a conference
Subscribe for More Information
July 25, 2014
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
July 24, 2014
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use